Chitosan stabilized camptothecin nanoemulsions: Development, evaluation and biodistribution in preclinical breast cancer animal mode

摘要: Clinical use of camptothecin (CPT) is hindered due to its poor water and oil solubility, active lactone ring instability non-targeted toxicity. Recently we reported formulation microemulsions with increased solubility for the improved treatment breast cancer. In this research chitosan stabilized nanoemulsions (CHI-CPT-NEs) were formulated improve cancer targeting efficiency CPT. The developed NEs characterized their droplet size distribution, stability in plasma evaluated in-vitro drug release, in-vivo potential, hemolytic cytotoxicity, genotoxicity biodistribution. CHI-CPT-NEs showed uniform extended release (61.65±1.57% at 24h), tolerable potential (16.4±1.4%), significant cytotoxicity (178±4.3ng/ml) against MCF-7 cells low DNA damage lymphocytes. In-vivo biodistribution study conducted 4T1-breast tumor xenograft BALB/c mice that 2495.22±174.66ng/gm was passively targeted by compared non-stabilized nanoemulsion (1677.58±134.21ng/gm). Thus, passive may provide a promising approach efficient therapy.